

Legend: SCAR – Severe cutaneous adverse reaction (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalised) Type A – Non-immune mediated adverse drug reactions Type B – Immune mediated adverse drug reaction a If TMP-SMX-associated rash within last two years, can consider dapsone rather than rechallenge b Drug fever, acute interstitial nephritis, fixed drug eruption c Oral single dose challenge and observe for two hours (TMP-SMX 80mg-400mg). Preferred prophylaxis strategy generally TMP-SMX 160mg-800mg daily or 3 times weekly. For all patients proceed with TMP-SMX desensitization or alternatively, dapsone therapy may be employed. Prescribe dapsone 100mg orally daily. Ensure G6PD deficiency screen negative prior to use. Only if required for PJP prophylaxis. If for alternative reason seek infectious diseases advice